Trials / Completed
CompletedNCT01839929
A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF
A Multicenter, Open-label, Single-arm, Non-inferiority Study to Assess the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF® in Stable Kidney Transplant Patients Converted From a PROGRAF® Based Immunosuppressive Regimen
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- Astellas Pharma Korea, Inc. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of tacrolimus modified release formulation Advagraf® after conversion from Prograf® in stable kidney transplant patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prograf | oral |
| DRUG | Advagraf | oral |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2013-04-25
- Last updated
- 2013-05-01
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01839929. Inclusion in this directory is not an endorsement.